The U.S. Food and Drug Administration (FDA) has approved the Animas Vibe, a combination insulin pump and continuous glucose monitor (CGM). It allows patients with Type 1 diabetes to monitor blood glucose levels mostly without a finger stick and adjust insulin delivery based on that data. Animas is a Johnson & Johnson company.
This is one step toward the widespread availability of an artificial pancreas , which would deliver multiple hormones such as insulin and glucagon automatically and effectively enough to closely mimic the natural way the body maintains blood sugar levels. A recent study published in The Lancet found that an artificial pancreas is more effective than conventional treatment for Type 1 diabetes with a patient-controlled insulin pump.
The Animas Vibe integrates Dexcom’s Platinum sensing CGM technology. The latest glucose readings are visible on the built-in device screen, as are glucose level trends over time. The CGM measures glucose levels every 5 minutes. The device offers insulin dosing in increments of 0.025 U/hr; patients can adjust dosing based on insulin-to-carb ratios, insulin sensitivity and blood glucose targets.
Comentarios recientes